Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089969688> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2089969688 endingPage "S64" @default.
- W2089969688 startingPage "S64" @default.
- W2089969688 abstract "Breakthrough cancer pain (BTCP) is commonly managed with formulations of transmucosal fentanyl. A novel sublingual formulation of fentanyl, fentanyl sublingual spray, has been developed to enhance the rate and extent of fentanyl absorption and potentially the onset of analgesia. This analysis presents results from the 26-day open-label titration phase of a phase 3, randomized, double-blind, placebo-controlled study. Opioid-tolerant patients with 1-4 episodes of BTCP/d were enrolled. For randomization into double-blind treatment, patients must have successfully titrated to a dose (100-1600 mcg) that provided effective analgesia for 2 consecutive BTCP episodes. The Treatment Satisfaction Questionnaire for Medication was assessed at screening to determine satisfaction with previous BTCP medication and at the end of titration to determine satisfaction with fentanyl sublingual spray. Of 130 patients undergoing titration, 98 (75%) achieved a successful dose; the median dose was 800 mcg, and the most common doses were 800 mcg (22.4%) and 1200 mcg (20.4%). Of 32 (25%) patients that withdrew from titration, only 3 (2.3%) were unable to establish an effective dose. At the end of titration, 89% were satisfied, very satisfied, or extremely satisfied with fentanyl sublingual spray, compared with 41% with their previous BTCP medication. Notably, 90% were at least satisfied with the onset of effect of fentanyl sublingual spray versus 21% in relation to previous BTCP treatment. Seventy-eight patients (60%) reported ≥1 adverse event (AE). Thirty-three AEs (25.4%) were considered probably related to treatment, the most common being nausea (6.2%) and somnolence (4.6%). These data demonstrate that in patients with BTCP, fentanyl sublingual spray can be safely titrated to an effective dose, and many prefer this treatment over previous BTCP medications. Technical editorial and medical writing assistance provided by Synchrony Medical, LLC, West Chester, PA, funded by INSYS Therapeutics, Phoenix, AZ." @default.
- W2089969688 created "2016-06-24" @default.
- W2089969688 creator A5017547088 @default.
- W2089969688 creator A5038320557 @default.
- W2089969688 creator A5048536513 @default.
- W2089969688 creator A5067097760 @default.
- W2089969688 creator A5087205593 @default.
- W2089969688 date "2012-04-01" @default.
- W2089969688 modified "2023-10-07" @default.
- W2089969688 title "Effective dose titration of fentanyl sublingual spray in patients with breakthrough cancer pain: results from the open-label phase of a double-blind, placebo-controlled study" @default.
- W2089969688 doi "https://doi.org/10.1016/j.jpain.2012.01.267" @default.
- W2089969688 hasPublicationYear "2012" @default.
- W2089969688 type Work @default.
- W2089969688 sameAs 2089969688 @default.
- W2089969688 citedByCount "0" @default.
- W2089969688 crossrefType "journal-article" @default.
- W2089969688 hasAuthorship W2089969688A5017547088 @default.
- W2089969688 hasAuthorship W2089969688A5038320557 @default.
- W2089969688 hasAuthorship W2089969688A5048536513 @default.
- W2089969688 hasAuthorship W2089969688A5067097760 @default.
- W2089969688 hasAuthorship W2089969688A5087205593 @default.
- W2089969688 hasBestOaLocation W20899696881 @default.
- W2089969688 hasConcept C121608353 @default.
- W2089969688 hasConcept C126322002 @default.
- W2089969688 hasConcept C141071460 @default.
- W2089969688 hasConcept C142724271 @default.
- W2089969688 hasConcept C168563851 @default.
- W2089969688 hasConcept C197934379 @default.
- W2089969688 hasConcept C204243189 @default.
- W2089969688 hasConcept C204787440 @default.
- W2089969688 hasConcept C27081682 @default.
- W2089969688 hasConcept C2775944032 @default.
- W2089969688 hasConcept C2778904085 @default.
- W2089969688 hasConcept C2780580376 @default.
- W2089969688 hasConcept C2781072394 @default.
- W2089969688 hasConcept C42219234 @default.
- W2089969688 hasConcept C71924100 @default.
- W2089969688 hasConcept C98274493 @default.
- W2089969688 hasConceptScore W2089969688C121608353 @default.
- W2089969688 hasConceptScore W2089969688C126322002 @default.
- W2089969688 hasConceptScore W2089969688C141071460 @default.
- W2089969688 hasConceptScore W2089969688C142724271 @default.
- W2089969688 hasConceptScore W2089969688C168563851 @default.
- W2089969688 hasConceptScore W2089969688C197934379 @default.
- W2089969688 hasConceptScore W2089969688C204243189 @default.
- W2089969688 hasConceptScore W2089969688C204787440 @default.
- W2089969688 hasConceptScore W2089969688C27081682 @default.
- W2089969688 hasConceptScore W2089969688C2775944032 @default.
- W2089969688 hasConceptScore W2089969688C2778904085 @default.
- W2089969688 hasConceptScore W2089969688C2780580376 @default.
- W2089969688 hasConceptScore W2089969688C2781072394 @default.
- W2089969688 hasConceptScore W2089969688C42219234 @default.
- W2089969688 hasConceptScore W2089969688C71924100 @default.
- W2089969688 hasConceptScore W2089969688C98274493 @default.
- W2089969688 hasIssue "4" @default.
- W2089969688 hasLocation W20899696881 @default.
- W2089969688 hasOpenAccess W2089969688 @default.
- W2089969688 hasPrimaryLocation W20899696881 @default.
- W2089969688 hasRelatedWork W1566699393 @default.
- W2089969688 hasRelatedWork W2110416084 @default.
- W2089969688 hasRelatedWork W2152092551 @default.
- W2089969688 hasRelatedWork W2307199660 @default.
- W2089969688 hasRelatedWork W2348323329 @default.
- W2089969688 hasRelatedWork W2354125488 @default.
- W2089969688 hasRelatedWork W2358448560 @default.
- W2089969688 hasRelatedWork W2362111834 @default.
- W2089969688 hasRelatedWork W2365301694 @default.
- W2089969688 hasRelatedWork W2368113853 @default.
- W2089969688 hasVolume "13" @default.
- W2089969688 isParatext "false" @default.
- W2089969688 isRetracted "false" @default.
- W2089969688 magId "2089969688" @default.
- W2089969688 workType "article" @default.